BeOne Medicines AG ONC
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 32.98% | 29.01% | 34.17% | 32.06% | 40.42% |
| Total Other Revenue | 101.25% | 91.14% | 198.42% | 121.96% | 111.86% |
| Total Revenue | 33.81% | 29.63% | 35.46% | 32.84% | 41.00% |
| Cost of Revenue | 10.37% | 6.03% | 1.34% | -11.30% | 15.28% |
| Gross Profit | 37.60% | 33.01% | 41.37% | 40.16% | 46.28% |
| SG&A Expenses | 12.19% | 10.28% | 20.86% | 10.03% | 16.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.77% | 12.43% | 14.23% | 8.77% | 11.35% |
| Operating Income | 156.68% | 269.85% | 2,150.96% | 332.97% | 235.63% |
| Income Before Tax | 178.85% | 213.87% | 1,140.26% | 274.86% | 249.70% |
| Income Tax Expenses | 14.92% | 1,342.95% | 62.29% | 24.36% | -3.14% |
| Earnings from Continuing Operations | 208.16% | 151.28% | 17,802.13% | 143.79% | 202.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 208.16% | 151.28% | 17,802.13% | 143.79% | 202.88% |
| EBIT | 156.68% | 269.85% | 2,150.96% | 332.97% | 235.63% |
| EBITDA | 129.31% | 209.10% | 577.00% | 822.86% | 496.46% |
| EPS Basic | 198.72% | 143.96% | 17,118.49% | 142.02% | 198.86% |
| Normalized Basic EPS | 147.35% | 192.49% | 988.00% | 331.38% | 256.39% |
| EPS Diluted | 212.50% | 166.67% | 17,005.26% | 136.29% | 188.89% |
| Normalized Diluted EPS | 149.12% | 192.86% | 983.97% | 322.05% | 250.51% |
| Average Basic Shares Outstanding | 3.16% | 3.01% | 3.77% | 4.21% | 4.07% |
| Average Diluted Shares Outstanding | 2.43% | 2.88% | 4.14% | 8.58% | 8.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |